This study found that the addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE. Clinicians should be aware of this potential complication when adding thalidomide to chemotherapeutic regimens.
The authors are indebted to Khanh Nghiem for performing protein C, protein S, antithrombin, factor VIII, and activated protein C resistance measurements, and to Ann Cullinane for performing the enzyme-linked immunosorbent assay for thrombin-antithrombin complexes. Both are members of the Hematology Service in the Department of Laboratory Medicine, W.G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland.Funding information
Funded by the Intramural Program of the National Cancer Institute, Bethesda, Maryland.
Address reprint requests to William D. Figg, Pharm.D., Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 5A01, MSC1910, 9000 Rockville Pike, Bethesda, MD 20892; e-mail: firstname.lastname@example.org.
Pharmacotherapy. 2003;23(3) © 2003 Pharmacotherapy Publications
Copyright © 1999, Pharmacotherapy Publications, Inc., All rights reserved.
Cite this: Increased Frequency of Venous Thromboembolism With the Combination of Docetaxel and Thalidomide in Patients With Metastatic Androgen-Independent Prostate Cancer - Medscape - Mar 01, 2003.